Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pain Away is an over-the-counter oral combination analgesic product containing **acetaminophen 250 mg**, **aspirin 250 mg**, and **caffeine 65 mg** in a non-drowsy, single-dose formulation. It is intended for symptomatic relief of common pain conditions including headache, muscle pain, menstrual cramps, toothache, minor arthritis pain, and fever. Pharmacologically, the product combines the central analgesic and antipyretic effects of acetaminophen with the analgesic, anti-inflammatory, and antipyretic effects of aspirin, while caffeine acts as an adjuvant that can enhance analgesic efficacy. This is a marketed consumer pain-relief product rather than a novel developmental biotech asset.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Pain Away.